Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-05-02

Clinical Trial Update: Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating lumateperone as adjunctive therapy for major depressive disorder has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Caplyta (lumateperone)

Snippet

Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2025-05-02